已核实 DOI PubMed 相关产品: 20

Metal ions-anchored bacterial outer membrane vesicles for enhanced ferroptosis induction and immune stimulation in targeted antitumor therapy

Journal 2024 · IF 10.6 · 22(1): 1-15 · 发表于 2024 年 8 月 9 日
作者: Sun Ying,Ma Yan-Yan,Shangguan Shijie,Ruan Yihang,Bai Tingjie,Xue Panpan,Zhuang Huilan,Cao Wenyu,Cai Huimei,Tang Enqi,Wu Zhou,Yang Mingzhen,Zeng Yixin,Sun Juan,Fan Yong,Zeng Xuemei,Yan Shuangqian
阅读全文 在 PubMed 查看

摘要

The activation of ferroptosis presents a versatile strategy for enhancing the antitumor immune responses in cancer therapy. However, developing ferroptosis inducers that combine high biocompatibility and therapeutic efficiency remains challenging. In this study, we propose a novel approach using biological nanoparticles derived from outer membrane vesicles (OMVs) of Escherichia coli for tumor treatment, aiming to activate ferroptosis and stimulate the immune responses. Specifically, we functionalize the OMVs by anchoring them with ferrous ions via electrostatic interactions and loading them with the STING agonist-4, followed by tumor-targeting DSPE-PEG-FA decoration, henceforth referred to as OMV/SaFeFA. The anchoring of ferrous ions endows the OMVs with peroxidase-like activity, capable of inducing cellular lipid peroxidation by catalyzing H 2 O 2 to • OH. Furthermore, OMV/SaFeFA exhibits pH-responsive release of ferrous ions and the agonist, along with tumor-targeting capabilities, enabling tumor-specific therapy while minimizing side effects. Notably, the concurrent activation of the STING pathway and ferroptosis elicits robust antitumor responses in colon tumor-bearing mouse models, leading to exceptional therapeutic efficacy and prolonged survival. Importantly, no acute toxicity was observed in mice receiving OMV/SaFeFA treatments, underscoring its potential for future tumor therapy and clinical translation.

本研究中使用的阿拉丁产品

20 款产品在本文中被引用